In yesterday’s Wall Street session, Evelo Biosciences Inc. (NASDAQ:EVLO) shares traded at $1.01, down -2.88% from the previous session.
6 analysts cover Evelo Biosciences Inc. (NASDAQ:EVLO), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $2.50, we find $5.50. Given the previous closing price of $1.04, this indicates a potential upside of 428.85 percent. EVLO stock price is now -41.40% away from the 50-day moving average and -52.20% away from the 200-day moving average. The market capitalization of the company currently stands at $118.26M.
The stock has received a hold rating from 2 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
With the price target maintained at $12, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Evelo Biosciences Inc. (NASDAQ: EVLO). On June 23, 2021, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $28, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, CARRIERE STEPHEN J, Principal Accounting Officer sold 151 shares of the company’s stock on Jan 23. The stock was sold for $160 at an average price of $1.06. Upon completion of the transaction, the Principal Accounting Officer now directly owns 203 shares in the company, valued at $205.03. An SEC document containing details of the transaction can be found on the SEC’s website. On May 27, Chief Medical Officer McHale Duncan bought 34,246 shares of the business’s stock. A total of $49,999 was incurred on buying the stock at an average price of $1.46. This leaves the insider owning 34,246 shares of the company worth $34588.46. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EVLO stock. A new stake in Evelo Biosciences Inc. shares was purchased by BRIDGEWAY CAPITAL MANAGEMENT, LLC during the first quarter worth $106,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $18,000 in shares of EVLO during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Evelo Biosciences Inc. valued at approximately $5,000. BARCLAYS PLC acquired a new stake in EVLO for approximately $3,000. UBS GROUP AG purchased a new stake in EVLO valued at around $3,000 in the second quarter. In total, there are 75 active investors with 83.30% ownership of the company’s stock.
On Tuesday morning Evelo Biosciences Inc. (NASDAQ: EVLO) stock kicked off with the opening price of $1.0900. During the past 12 months, Evelo Biosciences Inc. has had a low of $0.97 and a high of $5.44. As of last week, the company has a debt-to-equity ratio of 5.03, a current ratio of 2.70, and a quick ratio of 2.70. The fifty day moving average price for EVLO is $1.7236 and a two-hundred day moving average price translates $2.1129 for the stock.
The latest earnings results from Evelo Biosciences Inc. (NASDAQ: EVLO) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.4, beating analysts’ expectations of -$0.43 by 0.03. This compares to -$0.63 EPS in the same period last year. The company reported revenue of $29.05 million for the quarter, compared to $32.71 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.18 percent.
Evelo Biosciences Inc.(EVLO) Company Profile
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.